Last reviewed · How we verify

NCT07021573: PRIMER

Protoporphyrin Imaging in Multispectral Evaluation of Resections

Not yet recruiting NA Last updated 9 September 2025
What this trial tests

NA trial testing KINEVO 900 S with BLUE 400 in Glioma in 80 participants. Not yet recruiting.

Timeline
30 September 2025
Primary endpoint
31 December 2025
1 May 2026

Quick facts

Lead sponsorMedical University Innsbruck
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationna
Designsequential
Maskingnone
Primary purposediagnostic
Enrollment80
Start date30 September 2025
Primary completion31 December 2025
Estimated completion1 May 2026
Sites10 locations across Austria, Switzerland, Germany

Drugs / interventions tested

Conditions studied

Sponsor

Medical University Innsbruck

Who can join

Adults 18 to 99, any sex, with Glioma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Observational non-interventional investigation to evaluate the potential of multispectral imaging in improving tumor visualization.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Glioma

Currently open trials in the same condition.

Other Medical University Innsbruck trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07021573.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing